Antimicrobial ReportsVancomycin Cerebrospinal Fluid Pharmacokinetics in Children with Cerebral Ventricular Shunt InfectionsAutmizguine, Julie MD*; Moran, Cassie DO†; Gonzalez, Daniel PharmD, PhD*‡; Capparelli, Edmund V. PharmD§; Smith, P. Brian MD, MPH, MHS*†; Grant, Gerald A MD†¶; Benjamin, Daniel K. Jr. MD, PhD, MPH*†; Cohen-Wolkowiez, Michael MD, PhD*†; Watt, Kevin M. MD*†Author Information From the *Duke Clinical Research Institute; †Department of Pediatrics, Duke University, Durham; ‡Division of Pharmacotherapy and Experimental Therapeutics, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, NC; §Department of Pediatric Pharmacology, University of California, San Diego, CA; and ¶Department of Neurosurgery, Duke University, Durham, NC. Accepted for publication April 7, 2014. J.A. receives support from Training Award, Fonds Irma-Levasseur, Pediatric Department, Sainte-Justine University Hospital Center. D.G. is funded by the National Institute of General Medical Sciences through a T32 grant (GM086330). E.V.C. receives support from the United States government for his work in pediatric and developmental clinical pharmacology (U54-HD071600-2,UM1-AI068632, HHSN261200800001E, HHSN275201000003, R01 NS074409-01A1). P.B.S. receives support for research from the National Institutes of Health and the US Department of Health and Human Services (NICHD DG is funded by the National Institute of General Medical Sciences through a T32 grant [GM086330], 1K23HD060040-01 and DHHS-1R18AE000028-01). G.A.G. receives support for research from the National Institutes of Health (K08NS075144-03). D.K.B. receives support from the United States government for his work in pediatric and neonatal clinical pharmacology (1R01HD057956-05, 1R01FD003519-04, 1K24HD058735-05 and NICHD contract HHSN2752010000031) and the nonprofit organization Thrasher Research Fund for his work in neonatal candidiasis (www.thrasherresearch.org); he also receives research support from industry for neonatal and pediatric drug development (www.dcri.duke.edu/research/coi.jsp). M.C.W. receives support for research from the National Institutes of Health (1K23HD064814); the Food and Drug Administration (1U01FD004858-01); the nonprofit organization Thrasher Research Fund (www.thrasherresearch.org) and from industry for drug development in adults and children (www.dcri.duke.edu/research/coi.jsp). K.M.W. receives support from NIGMS (1T32GM086330-01A1) and the Thrasher Research Fund (www.thrasherresearch.org) for his work in pediatric clinical pharmacology. Address for correspondence: Kevin M. Watt, MD, Duke University, Pediatrics, Duke Clinical Research Institute; P.O. Box 3046, Durham, NC 27710. E-mail: firstname.lastname@example.org. The Pediatric Infectious Disease Journal: October 2014 - Volume 33 - Issue 10 - p e270–e272 doi: 10.1097/INF.0000000000000385 Buy Metrics Abstract This study described the cerebrospinal fluid (CSF) exposure of vancomycin in 8 children prescribed intravenous vancomycin therapy for cerebral ventricular shunt infection. Vancomycin CSF concentrations ranged from 0.06 to 9.13 mg/L and the CSF: plasma ratio ranged from 0 to 0.66. Two of 3 children with a staphylococcal CSF infection had CSF concentrations greater than minimal inhibitory concentration at the end of the dosing interval. © 2014 by Lippincott Williams & Wilkins, Inc.